Cohlhepp Ryan 4

What Happened

• Ryan Cohlhepp, President, COO and director of Bicara Therapeutics, sold 3,828 shares on January 22, 2026. The reported weighted-average price was $18.10, for aggregate proceeds of $69,296. The Form 4 was filed on January 26, 2026.
• This was a sale (transaction code S) executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: January 22, 2026
• Filing date: January 26, 2026 (filed within the SEC’s 2-business-day window)
• Shares sold: 3,828
• Price: weighted average $18.10; individual trades ranged $18.00–$18.19
• Proceeds: $69,296
• Shares owned after transaction: Not specified in the provided filing excerpt
• Footnotes: (F1) Sale executed under a 10b5-1 plan adopted Feb 12, 2025. (F2) Price is a weighted average; reporting person can provide per-price breakdown on request.

Context

• Trades under a Rule 10b5-1 plan are pre-arranged and typically scheduled in advance, so they often reflect plan parameters rather than the insider’s current view of the company. Sales are generally less informative than purchases for gauging insider sentiment.